Answers are grounded in this paper and cite their sources.
Background The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.Methods By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy (ChT) during the first surge of the pandemic.Results The adjusted risk of death was higher in patients treated with ChT + Pembrolizumab (HR 4.6, 1.2–17.4, p = 0.02). The SARS-CoV-2-related mortality rate was higher in patients treated with ChT + Pembrolizumab (p = 0.03), ≥70 years (p = 0.03) and current smokers (p = 0.17).Conclusions The addition of ChT to immunotherapy could be associated with increased risk of mortality and higher SARS-CoV-2-related mortality rate.
No takes yet. Share an insight, caveat, or question.
Banna et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: